In combination with a nonsteroidal aromatase inhibitor, abemaciclib was found to significantly increase progression free survival for patients with advanced HR+, HER2− breast cancer, relative to treatment with the aromatase inhibitor alone [49]. This evidence concerns the gene CYP19A1 and breast carcinoma.